| Autor: |
Marie-Claude Brulhart-Meynet, Vincent Braunersreuther, Jonas Brinck, Fabrizio Montecucco, Jean-Christophe Prost, Aurelien Thomas, Katia Galan, Graziano Pelli, Sarah Pedretti, Nicolas Vuilleumier, François Mach, Sandrine Lecour, Richard W James, Miguel A Frias |
| Jazyk: |
angličtina |
| Rok vydání: |
2015 |
| Předmět: |
|
| Zdroj: |
PLoS ONE, Vol 10, Iss 3, p e0119664 (2015) |
| Druh dokumentu: |
article |
| ISSN: |
1932-6203 |
| DOI: |
10.1371/journal.pone.0119664 |
| Popis: |
BackgroundNew evidence shows that high density lipoproteins (HDL) have protective effects beyond their role in reverse cholesterol transport. Reconstituted HDL (rHDL) offer an attractive means of clinically exploiting these novel effects including cardioprotection against ischemia reperfusion injury (IRI). However, basic rHDL composition is limited to apolipoprotein AI (apoAI) and phospholipids; addition of bioactive compound may enhance its beneficial effects.ObjectiveThe aim of this study was to investigate the role of rHDL in post-ischemic model, and to analyze the potential impact of sphingosine-1-phosphate (S1P) in rHDL formulations.Methods and resultsThe impact of HDL on IRI was investigated using complementary in vivo, ex vivo and in vitro IRI models. Acute post-ischemic treatment with native HDL significantly reduced infarct size and cell death in the ex vivo, isolated heart (Langendorff) model and the in vivo model (-48%, pConclusionHDL afford protection against IRI in a clinically relevant model (post-ischemia). rHDL is significantly protective if supplemented with S1P. The protective impact of HDL appears to target directly the cardiomyocyte. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
